DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials And Therapies Analysis With Key MOA And ROA Insights By Delveinsight Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics

(MENAFN- GetNews)

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“DUB Inhibitors Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market.

The DUB Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the DUB Inhibitors Pipeline Report:

• Companies across the globe are diligently working toward developing novel DUB Inhibitors treatment therapies with a considerable amount of success over the years.

• DUB Inhibitors companies working in the treatment market are bromide Cothera, USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others, are developing therapies for the DUB Inhibitors treatment

• Emerging DUB Inhibitors therapies in the different phases of clinical trials are- Sepantronium, Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others are expected to have a significant impact on the DUB Inhibitors market in the coming years.

• The emerging pipeline for DUB inhibitors is varied, featuring several promising candidates such as ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), sepantronium bromide/PC-002/YM155 (Cothera Bioscience), TNG348 (Tango Therapeutics), ASN3186/AT012 (Asieris Pharmaceuticals), among others . Most of these candidates are currently in the early stages of development, either preclinical or Phase I.

• In July 2024, Mission Therapeutics has received USD 5.2 million in funding from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Parkinson's UK to support the development of its potential disease-modifying Parkinson's treatment, MTX325.

• In July 2024, Molecure formed a strategic research partnership with Avicenna Biosciences to advance the discovery and development of innovative small-molecule drugs targeting USP7.

DUB Inhibitors Overview

DUB inhibitors, or deubiquitinase inhibitors, are a class of compounds that target enzymes called deubiquitinases (DUBs). These enzymes are responsible for removing ubiquitin molecules from proteins, a process known as deubiquitination. Ubiquitination and deubiquitination play essential roles in regulating various cellular processes, including protein degradation, DNA repair, signal transduction, and immune response.

Get a Free Sample PDF Report to know more about DUB Inhibitors Pipeline Therapeutic Assessment-

Emerging DUB Inhibitors Drugs Under Different Phases of Clinical Development Include:

• Sepantronium: bromide Cothera

• Research program: USP7 Ubiquigent

• Small molecules: Carmot Therapeutics

• OAT-4828: Molecure

• MTX325: Mission Therapeutics

• TNG348: Tango Therapeutics

• MTX652: Mission Therapeutics

• KSQ-4279: KSQ Therapeutics

• PC-002: Cothera Bioscience

• USP30 inhibitor program: Mission Therapeutics

• USP7 inhibitors program: Almac Discovery

• Research programme: deubiquitinating enzyme inhibitors: Carmot Therapeutics

• MuRF1 inhibitors: Progenra

• VLX1570: Vivolux

DUB Inhibitors Pipeline Therapeutics Assessment

• DUB Inhibitors Assessment by Product Type

• DUB Inhibitors By Stage and Product Type

• DUB Inhibitors Assessment by Route of Administration

• DUB Inhibitors By Stage and Route of Administration

• DUB Inhibitors Assessment by Molecule Type

• DUB Inhibitors by Stage and Molecule Type

DelveInsight's DUB Inhibitors Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further DUB Inhibitors product details are provided in the report. Download the DUB Inhibitors pipeline report to learn more about the emerging DUB Inhibitors therapies

Some of the key companies in the DUB Inhibitors Therapeutics Market include:

Key companies developing therapies for DUB Inhibitors are - Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics, Carmot Therapeutics, Progenra, Hybrigenics, and others.

DUB Inhibitors Pipeline Analysis:

The DUB Inhibitors pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of DUB Inhibitors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DUB Inhibitors Treatment.

• DUB Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• DUB Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DUB Inhibitors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about DUB Inhibitors drugs and therapies

DUB Inhibitors Pipeline Market Drivers

• Novel candidates for target-directed drug development, DUBs play major roles in diverse cellular-processes are some of the important factors that are fueling the DUB Inhibitors Market.

DUB Inhibitors Pipeline Market Barriers

• However, lack of in-depth studies to understand their natural regulatory mechanisms, inhibitors developed could have severe adverse effects by affecting non-target pathways and other factors are creating obstacles in the DUB Inhibitors Market growth.

Scope of DUB Inhibitors Pipeline Drug Insight

• Coverage: Global

• Key DUB Inhibitors Companies: bromide Cothera, USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others

• Key DUB Inhibitors Therapies: Sepantronium, Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others

• DUB Inhibitors Therapeutic Assessment: DUB Inhibitors current marketed and DUB Inhibitors emerging therapies

• DUB Inhibitors Market Dynamics: DUB Inhibitors market drivers and DUB Inhibitors market barriers

Request for Sample PDF Report for DUB Inhibitors Pipeline Assessment and clinical trials

Table of Contents

1. DUB Inhibitors Report Introduction

2. DUB Inhibitors Executive Summary

3. DUB Inhibitors Overview

4. DUB Inhibitors- Analytical Perspective In-depth Commercial Assessment

5. DUB Inhibitors Pipeline Therapeutics

6. DUB Inhibitors Late Stage Products (Phase II/III)

7. DUB Inhibitors Mid Stage Products (Phase II)

8. DUB Inhibitors Early Stage Products (Phase I)

9. DUB Inhibitors Preclinical Stage Products

10. DUB Inhibitors Therapeutics Assessment

11. DUB Inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. DUB Inhibitors Key Companies

14. DUB Inhibitors Key Products

15. DUB Inhibitors Unmet Needs

16 . DUB Inhibitors Market Drivers and Barriers

17. DUB Inhibitors Future Perspectives and Conclusion

18. DUB Inhibitors Analyst Views

19. Appendix

20. About DelveInsight

Latest Reports:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN15082025003238003268ID1109933804